Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

New research explores the wide world of the positives, and potential drawbacks, of new obesity medications. And each brings a new consideration for physicians.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Pharma giant Novo Nordisk, the company behind Wegovy and Ozempic, expects to launch six products in the next five years. Leading the pack of new drugs will be CagriSema.

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid a lack of clarity over trial results that hammered its shares in ...

Freshly Cut OZEMPIC Vs Food: What You Should Know Posted: February 2, 2025 | Last updated: February 2, 2025 "Bobby Parrish is the expert behind FlavCity, specializing in healthy, budget-friendly ...

As of January 2025, Ozempic's weekly prescriptions were reported at 576,790, while Mounjaro (tirzepatide ... shortages were limited to the lowest dose for Wegovy. Novo Nordisk has been actively ...

Looking for weight loss options? GLP-1 agonist medications, originally designed to manage type 2 diabetes, are now FDA-approved for weight management. Klarity connects you with healthcare ...

*Refers to the latest 2 years of stltoday.com stories. Cancel anytime. Klarity - Weight Loss Looking for weight loss options? GLP-1 agonist medications, originally designed to manage type 2 ...

Novo Nordisk said the Food and Drug Administration approved the diabetes-drug Ozempic to be used to help kidney-disease patients. Ozempic, or semaglutide, can now be used to reduce the risk of ...